|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Future Challenges for Target Validation | ||||||||||||||||
| July 01, 2003 | ||||||||||||||||
|
marcus evans Life Sciences, TBA, London 3 November 2003 to 4 November 2003 With an increased number of genes available for experimentation and little information on their functions, the process of drug-discovery has been introduced to a new bottleneck. The trade-off between cost and throughput is a novel factor, which affects acutely decision making for both pharmaceutical and biotech companies. Successfully identifying targets with therapeutic potential at an early stage reduces the failure rate at further stages of research and subsequently diminishes cost and risk. This event explores the new trends within the scientific community towards the implementation and advancement of new methodologies for the enhancement of target validation at early stages. The suitability and effectiveness of these methodologies is examined via practical case studies, which underline how the current challenges can be dealt with in a more successful way. |
||||||||||||||||
| Organized by: | marcus evans Life Sciences | |||||||||||||||
| Invited Speakers: | ||||||||||||||||
| Deadline for Abstracts: | ||||||||||||||||
| Registration: | ||||||||||||||||
| E-mail: | olas@marcusevansuk.com | |||||||||||||||
| Posted by: | Ola Samuelsson | |||||||||||||||
| Host: | 194.74.216.2 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||